PGLYRP2 drives hepatocyte-intrinsic innate immunity by trapping and clearing hepatitis B virus
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci188083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Ying Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Harbin Institute of Technology, Harbin, China. Hauptthemen laut MEDLINE: Hepatitis B virus, Hepatocytes, Immunity, Innate, Hepatitis B. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Spontaneous clearance of hepatitis B virus (HBV) is frequent in adults (95%) but rare in infants (5%), emphasizing the critical role of age-related hepatic immunocompetence. However, the underlying mechanisms of hepatocyte-specific immunosurveillance and age-dependent HBV clearance remain unclear. Here, we identified PGLYRP2 as a hepatocyte-specific pattern recognition receptor with age-dependent expression, and demonstrated that phase separation of PGLYRP2 was a critical driver of spontaneous HBV clearance in hepatocytes. Mechanistically, PGLYRP2 recognized and potentially eliminated covalently closed circular DNA via phase separation, coordinated by its intrinsically disordered region and HBV DNA-binding domain (PGLYRP2 IDR/209–377 ) in the nucleus. Additionally, PGLYRP2 suppressed HBV capsid assembly by directly interacting with the viral capsid, mediated by its PGRP domain. This interaction promoted the nucleocytoplasmic translocation of PGLYRP2 and subsequent secretion of the PGLYRP2/HBV capsid complex, thereby bolstering the hepatic antiviral response. Pathogenic variants or deletions in PGLYRP2 impaired its ability to inhibit HBV replication, highlighting its essential role in hepatocyte-intrinsic immunity. These findings suggest that targeting the PGLYRP2-mediated host-virus interaction may offer a potential therapeutic strategy for the development of anti-HBV treatments, representing a promising avenue for achieving a functional cure for HBV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
- International Research Center for Regenerative Medicine, Boao International Hospital, Qionghai, China.
- Biomedical Postgraduate Workstation of Heilongjiang Province, Harbin, China.
- Department of Surgery Oncology, Sixth Affiliated Hospital of Harbin Medical University, Harbin, China.
- Department of Surgery Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- School of Medicine and Health, Harbin Institute of Technology, Harbin, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, Y., Ma, H., Zhang, Y., He, T., Li, B., Ren, H., Feng, J., Sheng, J., Li, K., Qian, Y., Wang, Y., Zhao, H., He, J., Li, H., Wu, H., Yao, Y., & Shi, M. (2025). PGLYRP2 drives hepatocyte-intrinsic innate immunity by trapping and clearing hepatitis B virus. Journal of Clinical Investigation. https://doi.org/10.1172/jci188083
Vancouver
Li Y, Ma H, Zhang Y, He T, Li B, Ren H, et al. PGLYRP2 drives hepatocyte-intrinsic innate immunity by trapping and clearing hepatitis B virus. Journal of Clinical Investigation. 2025. doi:10.1172/jci188083
BibTeX
@article{Li2025,
author = {Li, Ying and Ma, Huihui and Zhang, Yongjian and He, Tinghui and Li, Binyang and Ren, Haoran and Feng, Jia and Sheng, Jie and Li, Kai and Qian, Yu and Wang, Yunfeng and Zhao, Haoran and He, Jie and Li, Huicheng and Wu, Hongjin and Yao, Yuanfei and Shi, Ming},
title = {PGLYRP2 drives hepatocyte-intrinsic innate immunity by trapping and clearing hepatitis B virus},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci188083}
}
EUVIMED